Mariona Chicon-Bosch

Dr. Mariona Chicon-Bosch

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2020 in Cells
Verified
Journal Article
Open access
PDF file
MCMariona Chicon-Bosch
Mariona Chicon-Bosch
OTOscar M Tirado
Oscar M Tirado
Bone sarcomas are rare cancers which often present with metastatic disease and are still associated with poor survival rates. Studies in the last decade have identified that exosomes, a type of extracellular vesicle released by cells, play an important role in tumour progression and dissemination. Through the transfer of their cargo (RNAs, proteins, and lipids) across cells, they are involved in cellular cross-talk and can induce changes in cellular behaviour. Exosomes have been shown to be important in metastasis organotropism, induction of angiogenesis and vascular permeability, the education of cells towards a pro-metastatic phenotype or the interaction between stromal and tumour cells. Due to the importance exosomes have in disease progression and the high incidence of metastasis in bone sarcomas, recent studies have evaluated the implications of these extracellular vesicles in bone sarcomas. In this review, we discuss the studies that evaluate the role of exosomes in osteosarcoma, Ewing sarcoma, and preliminary data on chondrosarcoma.

1 April 2020 in Cancer Letters
Verified
Journal Article
Closed access
OAOlga Almacellas-Rabaiget
Olga Almacellas-Rabaiget
PMPaola Monaco
Paola Monaco
JHJuan Huertas-Martinez
Juan Huertas-Martinez
SGSilvia García-Monclús
Silvia García-Monclús
MCMariona Chicon-Bosch
Mariona Chicon-Bosch
OTOscar M Tirado
Oscar M Tirado

5 January 2025 in Molecular Oncology
Verified
Journal Article
Open access
MCMariona Chicon-Bosch
Mariona Chicon-Bosch
SSSara Sánchez‐Serra
Sara Sánchez‐Serra
MRMarta Rosàs‐Lapeña
Marta Rosàs‐Lapeña
NCNicolás Costa‐Fraga
Nicolás Costa‐Fraga
JBJudit Besalú‐Velázquez
Judit Besalú‐Velázquez
OTOscar M Tirado
Oscar M Tirado
Ewing sarcoma (EWS) is the second most common bone tumor affecting children and young adults, with dismal outcomes for patients with metastasis at diagnosis. Mechanisms leading to metastasis remain poorly understood. To deepen our knowledge on EWS progression, we have profiled tumors and metastases from a spontaneous metastasis mouse model using a multi‐omics approach. Combining transcriptomics, proteomics, and methylomics analyses, we identified signaling cascades and candidate genes enriched in metastases that could be modulating aggressiveness in EWS. Phenotypical validation of two of these candidates, cyclic AMP‐responsive element‐binding protein 1 (CREB1) and lipoxygenase homology domain‐containing protein 1 (LOXHD1), showed an association with migration and clonogenic abilities. Moreover, previously described CREB1 downstream targets were present amongst the metastatic‐enriched results. Combining the different omics datasets, we identified FYVE, RhoGEF, and PH domain‐containing protein 4 (FGD4) as a CREB1 target interconnecting the different EWS biological layers (RNA, protein and methylation status) and whose high expression is associated with worse clinical outcome. Further studies will provide insight into EWS metastasis mechanisms and ultimately improve survival rates for EWS patients.

25 December 2025 in bioRxiv
Verified
Preprint
Open access
SSSara Sanchez-Serra
Sara Sanchez-Serra
MCMariona Chicon-Bosch
Mariona Chicon-Bosch
NMNuria Martorell-Villanueva
Nuria Martorell-Villanueva
ECEduardo Candeal
Eduardo Candeal
IJIgnasi Jarne-Sanz
Ignasi Jarne-Sanz
OTOscar M Tirado
Oscar M Tirado
Metastatic Ewing sarcoma (EwS) remains a major clinical challenge, highlighting the need to identify molecular drivers of disease dissemination. Through integrated transcriptomic, functional, and mechanistic analyses, we identify PARP14 as a key regulator of EwS metastatic progression. PARP14 is consistently upregulated in metastatic lesions across spontaneous and xenograft mouse models as well as in patient samples. Genetic and pharmacologic depletion of PARP14 (via siRNA knockdown, CRISPR-Cas9 knockout, or PROTAC-mediated degradation) significantly impaired EwS cell migration and invasion in vitro, without affecting proliferation or clonogenic capacity. In vivo, PARP14 loss delayed tumor growth and reduced metastatic burden, supporting a functional role in disease progression. Conversely, IFNγ-induced PARP14 upregulation and stable overexpression enhanced EwS cell migration and increased lung metastasis formation. Transcriptomic profiling of PARP14-deficient cells revealed downregulation of invasive signatures and enrichment of inflammatory and p53-related pathways, together with gene sets associated with chromatin remodeling. Subcellular fractionation and interactome analyses showed that PARP14 localizes to cytoplasmic, nuclear, and chromatin-associated compartments, and interacts with chromatin, cytoskeletal and ECM regulators. ChIP analyses further demonstrated PARP14 binding to promoters enriched for NRF1 motifs, suggesting a role as a transcriptional co-regulator influencing gene networks relevant to EwS progression. Together, our results establish PARP14 as a contributor to EwS dissemination and uncover a previously unappreciated chromatin-associated role for this protein, supporting its potential as both a biomarker and therapeutic target in metastatic EwS.